Compare UA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UA | STOK |
|---|---|---|
| Founded | 1996 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2005 | 2019 |
| Metric | UA | STOK |
|---|---|---|
| Price | $4.76 | $24.69 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 14 |
| Target Price | N/A | ★ $46.46 |
| AVG Volume (30 Days) | ★ 2.6M | 734.9K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $4,966,370,000.00 | $184,420,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.75 | $39.98 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $3.95 | $20.32 |
| 52 Week High | $7.91 | $40.22 |
| Indicator | UA | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 34.50 |
| Support Level | $4.16 | N/A |
| Resistance Level | $5.26 | $33.92 |
| Average True Range (ATR) | 0.16 | 1.19 |
| MACD | 0.07 | -0.03 |
| Stochastic Oscillator | 76.78 | 25.08 |
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America, Asia-Pacific, Europe, and Latin America. Consumers of its performance-based clothing and shoes include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through wholesale partners, company-owned digital channels, and approximately 440 company-owned outlet and full-price stores. The Baltimore-based firm was founded in 1996 and is led by controlling shareholder Kevin Plank.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.